12:00 AM
 | 
May 25, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AYX1: Completed Phase II enrollment

Adynxx completed enrollment of 120 patients in the double-blind, placebo-controlled, U.S. Phase II ADYX003 trial evaluating single intrathecal injections of 660 and 1,100 mg AYX1 given prior to unilateral...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >